SGLT-2 Inhibitor: Difference between revisions
Elcatracho (talk | contribs) (→Common) |
(Add See Also section) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 9: | Line 9: | ||
===Serious=== | ===Serious=== | ||
*Euglycemic [[DKA]]<ref>[https://www.fda.gov/Drugs/DrugSafety/ucm446845.htm FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood]</ref> | *Euglycemic [[DKA]]<ref>[https://www.fda.gov/Drugs/DrugSafety/ucm446845.htm FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood]</ref> | ||
*Fournier's gangrene (rare) | |||
===Common=== | ===Common=== | ||
| Line 18: | Line 19: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule | *Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule | ||
==See Also== | |||
*[[Diabetes medications]] | |||
*[[Diabetic ketoacidosis]] | |||
*[[Hyperglycemia]] | |||
==References== | ==References== | ||
Latest revision as of 09:14, 22 March 2026
Administration
- Type: Oral Diabetes medication
- Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
- UTI
- Genital candidiasis
- Weight loss
- Dehydration/Orthostasis
Mechanism of Action
- Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule